## VA Schedule for Rating Disabilities – Cardiovascular System Side-by-Side Comparison Handout Two

#### Historical Rating Schedule Effective July 12, 1998 – November 13, 2021

## § 4.100 Application of the evaluation criteria for diagnostic codes 7000-7007, 7011, and 7015-7020.

- (a) Whether or not cardiac hypertrophy or dilatation (documented by electrocardiogram, echocardiogram, or X-ray) is present and whether or not there is a need for continuous medication must be ascertained in all cases.
- (b) Even if the requirement for a 10% (based on the need for continuous medication) or 30% (based on the presence of cardiac hypertrophy or dilatation) evaluation is met, METs testing is required in all cases except:
- (1) When there is a medical contraindication.
- (2) When the left ventricular ejection fraction has been measured and is 50% or less.
- (3) When chronic congestive heart failure is present or there has been more than one episode of congestive heart failure within the past year.
- (4) When a 100% evaluation can be assigned on another basis.
- (c) If left ventricular ejection fraction (LVEF) testing is not of record, evaluate based on the alternative criteria unless the examiner states that the LVEF test is needed in a particular case because the available medical information does not sufficiently reflect the severity of the veteran's cardiovascular disability.

#### Updated (New) Rating Schedule Effective November 14, 2021

## § 4.100 Application of the evaluation criteria for diagnostic codes 7000-7007, 7011, and 7015-7020.

- (a) Whether or not cardiac hypertrophy or dilatation (documented by electrocardiogram, echocardiogram, or X-ray) is present and whether or not there is a need for continuous medication must be ascertained in all cases.
- (b) Even if the requirement for a 10% (based on the need for continuous medication) or 30% (based on the presence of cardiac hypertrophy or dilatation) evaluation is met, METs testing is required in all cases except:

1

- (1) When there is a medical contraindication.
- (2) When a 100% evaluation can be assigned on another basis.

§§ 4.101-4.103 [Reserved]

§§ 4.101-4.103 [Reserved]

#### § 4.104 Schedule of ratings - cardiovascular system

#### **Diseases of the Heart**

Note (1): Evaluate cor pulmonale, which is a form of secondary heart disease, as part of the pulmonary condition that causes it.

Note (2): One MET (metabolic equivalent) is the energy cost of standing quietly at rest and represents an oxygen uptake of 3.5 milliliters per kilogram of body weight per minute. When the level of METs at which dyspnea, fatigue, angina, dizziness, or syncope develops is required for evaluation, and a laboratory determination of METs by exercise testing cannot be done for medical reasons, an estimation by a medical examiner of the level of activity (expressed in METs and supported by specific examples, such as slow stair climbing or shoveling snow) that results in dyspnea, fatigue, angina, dizziness, or syncope may be used.

Unless otherwise directed, use this general rating formula to evaluate diseases of the heart.

Note (1): Evaluate cor pulmonale, which is a form of secondary heart disease, as part of the pulmonary condition that causes it.

Note (2): One MET (metabolic equivalent) is the energy cost of standing quietly at rest and represents an oxygen uptake of 3.5 milliliters per kilogram of body weight per minute. When the level of METs at which breathlessness, fatigue, angina, dizziness, or syncope develops is required for evaluation, and a laboratory determination of METs by exercise testing cannot be done for medical reasons, a medical examiner may estimate the level of activity (expressed in METs and supported by specific examples, such as slow stair climbing or shoveling snow) that results in those symptoms.

Note (3): For this general formula, heart failure symptoms include, but are not limited to, breathlessness, fatigue, angina, dizziness, arrhythmia, palpitations, or syncope.

Workload of 3.0 METs or less results in heart failure symptoms

Workload of 3.1–5.0 METs results in heart failure symptoms

Workload of 5.1–7.0 METs results in heart failure symptoms; or evidence of cardiac hypertrophy or dilatation confirmed by echocardiogram or equivalent (e.g., multigated acquisition scan or magnetic resonance imaging)

Workload of 7.1–10.0 METs results in heart failure symptoms; or continuous 10 medication required for control

#### 7000 Valvular heart disease (including rheumatic heart disease):

During active infection with valvular heart damage and for three months
following cessation of therapy for the active infection
Thereafter, with valvular heart disease (documented by findings on physical examination and either echocardiogram, Doppler echocardiogram, or cardiac catheterization) resulting in:

Chronic congestive heart failure, or: workload of 3 METs or less results in

Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent

#### 7000 Valvular heart disease (including rheumatic heart disease):

During active infection with cardiac involvement and for three months following cessation of therapy for the active infection

2

Thereafter, with diagnosis confirmed by findings on physical examination and either echocardiogram, Doppler echocardiogram, or cardiac catheterization, use the General Rating Formula.

More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in	60
dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular	
dysfunction with an ejection fraction of 30 to 50 percent	
Workload of greater than 5 METs but not greater than 7 METs results in	30
dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac	
hypertrophy or dilatation on electro-cardiogram, echocardiogram, or X-ray	
Workload of greater than 7 METs but not greater than 10 METs results in	10
dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication	
required	

#### 7001 Endocarditis:

For three months following cessation of therapy for active infection with cardiac involvement

Thereafter, with endocarditis (documented by findings on physical examination and either echocardiogram, Doppler echocardiogram, or cardiac catheterization) resulting in:

Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent

More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electrocardiogram, echocardiogram, or X-ray

Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required

#### 7002 Pericarditis:

For three months following cessation of therapy for active infection with cardiac involvement

Thereafter, with documented pericarditis resulting in:

Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent.

#### 7001 Endocarditis:

100

100

60

30

10

100

100

During active infection with cardiac involvement and for three months following cessation of therapy for the active infection

100

100

3

Thereafter, with diagnosis confirmed by findings on physical examination and either echocardiogram, Doppler echocardiogram, or cardiac catheterization, use the General Rating Formula.

#### 7002 Pericarditis:

During active infection with cardiac involvement and for three months following cessation of therapy for the active infection

Thereafter, with diagnosis confirmed by findings on physical examination and either echocardiogram, Doppler echocardiogram, or cardiac catheterization, use the General Rating Formula.

More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent	60
Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electro-cardiogram, echocardiogram, or X-ray	30
Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required	10

#### 7003 Pericardial adhesions:

Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent

More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent

Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electro-cardiogram, echocardiogram, or X-ray

Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required

#### 7004 Syphilitic heart disease:

Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent
More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent
Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electrocardiogram, echocardiogram, or X-ray

Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required

#### 7003 Pericardial adhesions:

Evaluate under the General Rating Formula.

#### 7004 Syphilitic heart disease:

Evaluate under the General Rating Formula.

Note: Evaluate syphilitic aortic aneurysms under DC 7110 (Aortic aneurysm: ascending, thoracic, abdominal).

November 2021

10

Note: Evaluate syphilitic aortic aneurysms under DC 7110 (aortic aneurysm).

#### 7005 Arteriosclerotic heart disease (Coronary artery disease):

With documented coronary artery disease resulting in:

Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent

More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent

Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electrocardiogram, echocardiogram, or X-ray

Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required

Note: If nonservice-connected arteriosclerotic heart disease is superimposed on service-connected valvular or other non-arteriosclerotic heart disease, request a medical opinion as to which condition is causing the current signs and symptoms.

#### 7005 Arteriosclerotic heart disease (coronary artery disease):

Evaluate under the General Rating Formula.

Note: If non-service-connected arteriosclerotic heart disease is superimposed on service-connected valvular or other non-arteriosclerotic heart disease, request a medical opinion as to which condition is causing the current signs and symptoms.

#### 7006 Myocardial infarction:

During and for three months following myocardial infarction, documented by laboratory tests

Thereafter:

With history of documented myocardial infarction, resulting in:

More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent

More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent

Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electrocardiogram, echocardiogram, or X-ray

#### 7006 Myocardial infarction:

During and for three months following myocardial infarction, confirmed by laboratory tests

100

5

Thereafter, use the General Rating Formula.

November 2021

10

100

100

60

Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required

10

#### 7007 Hypertensive heart disease:

Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent

More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent

Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electrocardiogram, echocardiogram, or X-ray

Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required

#### 7008 Hyperthyroid heart disease.

Rate under the appropriate cardiovascular diagnostic code, depending on particular findings.

7009 NEW!!

#### 7007 Hypertensive heart disease:

Evaluate under the General Rating Formula.

#### 7008 No change

For DCs 7009, 7010, 7011, and 7015, a single evaluation will be assigned under the diagnostic code which reflects the predominant disability picture.

## 7009 Bradycardia (Bradyarrhythmia), symptomatic, requiring permanent pacemaker implantation:

100

For one month following hospital discharge for implantation or re-implantation:

Thereafter, use the General Rating Formula.

Note (1): Bradycardia (bradyarrhythmia) refers to conduction abnormalities that produce a heart rate less than 60 beats/min. There are five general classes of bradyarrhythmias: sinus bradycardia, including sinoatrial block; atrioventricular (AV) junctional (nodal) escape rhythm; AV heart block (second or third degree) or AV dissociation; atrial fibrillation or flutter with a slow ventricular response; and idioventricular escape rhythm.

Note (2): Asymptomatic bradycardia (bradyarrhythmia) is a medical finding only. It is not a disability subject to compensation.

7010 Supraventricular arrhythmias:	
Paroxysmal atrial fibrillation or other supraventricular tachycardia, with more than four episodes per year documented by ECG or Holter monitor	30
Permanent atrial fibrillation (lone atrial fibrillation), or; one to four episodes per year of paroxysmal atrial fibrillation or other supraventricular tachycardia documented by ECG or Holter monitor	10

#### 7011 Ventricular arrhythmias (sustained):

For indefinite period from date of hospital admission for initial evaluation and medical therapy for a sustained ventricular arrhythmia, or; for indefinite period from date of hospital admission for ventricular aneurysmectomy, or; with an automatic implantable Cardioverter-Defibrillator (AICD) in place

Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent

More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent

Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electrocardiogram, echocardiogram, or X-ray

Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required

#### 7010 Supraventricular tachycardia:

Confirmed by ECG, with five or more treatment interventions per year

Confirmed by ECG, with one to four treatment interventions per year; or, confirmed by ECG with either continuous use of oral medications to control or use of yagal maneuvers to control

30

10

100

Note (1): Examples of supraventricular tachycardia include, but are not limited to, atrial fibrillation, atrial flutter, sinus tachycardia, sinoatrial nodal reentrant tachycardia, atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia, atrial tachycardia, junctional tachycardia, and multifocal atrial tachycardia.

Note (2): For the purposes of this diagnostic code, a treatment intervention occurs whenever a symptomatic patient requires intravenous pharmacologic adjustment, cardioversion, and/or ablation for symptom relief.

#### 7011 Ventricular arrhythmias (sustained):

For an indefinite period from the date of inpatient hospital admission for initial medical therapy for a sustained ventricular arrhythmia; or, for an indefinite period from the date of inpatient hospital admission for ventricular aneurysmectomy; or, with an automatic implantable cardioverter-defibrillator (AICD) in place

Note: When inpatient hospitalization for sustained ventricular arrhythmia or ventricular aneurysmectomy is required, a 100 percent evaluation begins on the date of hospital admission with a mandatory VA examination six months following hospital discharge. Evaluate post-surgical residuals under the General Rating Formula. Apply the provisions of § 3.105(e) of this chapter to any change in evaluation based upon that or any subsequent examination.

November 2021

100

100

60

30

Note: A rating of 100 percent shall be assigned from the date of hospital admission for initial evaluation and medical therapy for a sustained ventricular arrhythmia or for ventricular aneurysmectomy. Six months following discharge, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter.

#### 7015 Atrioventricular block:

Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent
More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent
Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electrocardiogram, echocardiogram, or X-ray

Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication or a pacemaker required

Note: Unusual cases of arrhythmia such as atrioventricular block associated with a supraventricular arrhythmia or pathological bradycardia should be submitted to the Director, Compensation Service. Simple delayed P-R conduction time, in the absence of other evidence of cardiac disease, is not a disability.

#### 7016 Heart valve replacement (prosthesis):

For indefinite period following date of hospital admission for valve replacement

Thereafter:

Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent

More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent

#### 7015 Atrioventricular block

Benign (First-Degree and Second-Degree, Type I):

Evaluate under the General Rating Formula.

Non-Benign (Second-Degree, Type II and Third-Degree): Evaluate under DC 7018 (implantable cardiac pacemakers).

#### 7016 Heart valve replacement (prosthesis):

For an indefinite period following date of hospital admission for valve replacement

Thereafter, use the General Rating Formula.

Note: Six months following discharge from inpatient hospitalization, disability evaluation shall be conducted by mandatory VA examination using the General Rating Formula. Apply the provisions of § 3.105(e) of this chapter to any change in evaluation based upon that or any subsequent examination

100

8

November 2021

10

100

Workload of greater than 5 METs but not greater than 7 METs results in
dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac
hypertrophy or dilatation on electrocardiogram, echocardiogram, or X-ray

Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required

Note: A rating of 100 percent shall be assigned as of the date of hospital admission for valve replacement. Six months following discharge, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter.

7017 Coronary bypass surgery:	
For three months following hospital admission for surgery	100
Thereafter:	
Chronic congestive heart failure, or; workload of 3 METs or less results in	100
dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular	
dysfunction with an ejection fraction of less than 30 percent	
More than one episode of acute congestive heart failure in the past year,	60
or; workload of greater than 3 METs but not greater than 5 METs results in	
dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular	
dysfunction with an ejection fraction of 30 to 50 percent	
Workload of greater than 5 METs but not greater than 7 METs results in	30
dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac	
hypertrophy or dilatation on electrocardiogram, echocardiogram, or X-ray	
Workload greater than 7 METs but not greater than 10 METs results in	10
dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication	

required

7017 Coronary bypass surgery:	
For three months following hospital admission for surgery	100
Thereafter, use the General Rating Formula.	

November 2021 9

30

#### 7018 Implantable cardiac pacemakers:

For two months following hospital admission for implantation or reimplantation

Thereafter:

Evaluate as supraventricular arrhythmias (DC 7010), ventricular arrhythmias (DC 7011), or atrioventricular block (DC 7015).

Minimum

Note: Evaluate implantable Cardioverter-Defibrillators (AICD's) under DC 7011.

#### 7019 Cardiac transplantation:

For an indefinite period from date of hospital admission for cardiac transplantation

Thereafter:

Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent

More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent

Minimum

Note: A rating of 100 percent shall be assigned as of the date of hospital admission for cardiac transplantation. One year following discharge, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter.

#### 7018 Implantable cardiac pacemakers:

For one month following hospital discharge for implantation or re-implantation

n

100

#### Thereafter:

100

10

100

100

60

30

Evaluate as supraventricular tachycardia (DC 7010), ventricular arrhythmias (DC 7011), or atrioventricular block (DC 7015).

Minimum

Note: Evaluate automatic implantable cardioverter-defibrillators (AICDs) under DC 7011.

#### 7019 Cardiac transplantation:

For a minimum of one year from the date of hospital admission for cardiac 100 transplantation

Thereafter:

Evaulate under the General Rating Formula.

Minimum 30

Note: One year following discharge from inpatient hospitalization, determine the appropriate disability rating by mandatory VA examination. Apply the provisions of § 3.105(e) of this chapter to any change in evaluation based upon that or any subsequent examination.

7020 Cardiomyopathy:	
Chronic congestive heart failure, or; workload of 3 METs or less results in	100
dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular	
dysfunction with an ejection fraction of less than 30 percent	
More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent	60
Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electrocardiogram, echocardiogram, or X-ray	30
Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication	10

required

#### 7020 Cardiomyopathy:

Evaluate under the General Rating Formula.

## VA Schedule for Rating Disabilities – Cardiovascular System Side-by-Side Comparison

### § 4.104 Schedule of ratings - cardiovascular system Diseases of the Arteries and Veins

60

10

#### Historical Rating Schedule Effective July 12, 1998 – November 13, 2021

# 7101 Hypertensive vascular disease (hypertension and isolated systolic hypertension): Diastolic pressure predominantly 130 or more

Diastolic pressure predominantly 120 or more

Diastolic pressure predominantly 110 or more, or; systolic pressure

predominantly 200 or more

40

20

Diastolic pressure predominantly 100 or more, or; systolic pressure predominantly 160 or more, or; minimum evaluation for an individual with a history of diastolic pressure predominantly 100 or more who requires continuous medication for control

Note (1): Hypertension or isolated systolic hypertension must be confirmed by readings taken two or more times on at least three different days. For purposes of this section, the term hypertension means that the diastolic blood pressure is predominantly 90mm. or greater, and isolated systolic hypertension means that the systolic blood pressure is predominantly 160mm. or greater with a diastolic blood pressure of less than 90mm.

Note (2): Evaluate hypertension due to aortic insufficiency or hyperthyroidism, which is usually the isolated systolic type, as part of the condition causing it rather than by a separate evaluation.

Note (3): Evaluate hypertension separately from hypertensive heart disease and other types of heart disease.

Updated (New) Rating Schedule Effective November 14, 2021

101 No change			

#### 7110 Aortic aneurysm:

If five centimeters or larger in diameter, or; if symptomatic, or; for indefinite period from date of hospital admission for surgical correction (including any type of graft insertion)

Precluding exertion 60

Evaluate residuals of surgical correction according to organ systems affected.

Note: A rating of 100 percent shall be assigned as of the date of admission for surgical correction. Six months following discharge, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter

#### 7111 Aneurysm, any large artery:

If symptomatic, or; for indefinite period from date of hospital admission for 100 surgical correction

Following surgery:

Ischemic limb pain at rest, and; either deep ischemic ulcers or 100 ankle/brachial index of 0.4 or less

Claudication on walking less than 25 yards on a level grade at 2 miles per hour, and; persistent coldness of the extremity, one or more deep ischemic ulcers. or ankle/brachial index of 0.5 or less

Claudication on walking between 25 and 100 yards on a level grade at 2 miles per hour, and; trophic changes (thin skin, absence of hair, dystrophic nails) or ankle/brachial index of 0.7 or less

Claudication on walking more than 100 yards, and; diminished peripheral pulses or ankle/brachial index of 0.9 or less

Note (1): The ankle/brachial index is the ratio of the systolic blood pressure at the ankle (determined by Doppler study) divided by the simultaneous brachial artery systolic blood pressure. The normal index is 1.0 or greater.

Note (2): These evaluations are for involvement of a single extremity. If more than one extremity is affected, evaluate each extremity separately and combine (under §4.25), using the bilateral factor, if applicable.

#### 7110 Aortic aneurysm: ascending, thoracic, or abdominal:

Evaluate at 100 percent if the aneurysm is any one of the following: five centimeters (cm) or larger in diameter; symptomatic (e.g., precludes exertion); or requires surgery

Otherwise

100

100

Evaluate non-cardiovascular residuals of surgical correction according to organ systems affected.

Note: When surgery is required, a 100 percent evaluation begins on the date a physician recommends surgical correction with a mandatory VA examination six months following hospital discharge. Evaluate post-surgical residuals under the General Rating Formula. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter.

#### 7111 Aneurysm, any large artery:

If symptomatic; or, for the period beginning on the date a physician recommends surgical correction and continuing for six months following discharge from inpatient hospital admission for surgical correction

Following surgery: Evaluate under DC 7114 (peripheral arterial disease).

Note: Six months following discharge from inpatient hospitalization for surgery, determine the appropriate disability rating by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter.

November 2021 13

100

60

40

Note (3): A rating of 100 percent shall be assigned as of the date of hospital admission for surgical correction. Six months following discharge, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter.

#### 7112 Aneurysm, any small artery:

Asymptomatic

Note: If symptomatic, evaluate according to body system affected. Following surgery, evaluate residuals under the body system affected.

#### 7113 Arteriovenous fistula, traumatic: With high output heart failure 100 Without heart failure but with enlarged heart, wide pulse pressure, and 60 tachycardia Without cardiac involvement but with edema, stasis dermatitis, and either ulceration or cellulitis: Lower extremity 50 Upper extremity 40 With edema or stasis dermatitis: Lower extremity 30 Upper extremity 20

#### 7112 No change

7113 Arteriovenous fistula, traumatic:	
With high-output heart failure	100
Without heart failure but with enlarged heart, wide pulse pressure, and	60
tachycardia	
Without cardiac involvement but with chronic edema, stasis dermatitis, and	
either ulceration or cellulitis:	
Lower extremity	50
Upper extremity	40
Without cardiac involvement but with chronic edema or stasis dermatitis:	
Lower extremity	30
,	20
Upper extremity	20

Ischemic limb pain at rest, and; either deep ischemic ulcers or ankle/brachial index of 0.4 or less	100
Claudication on walking less than 25 yards on a level grade at 2 miles per hour, and; either persistent coldness of the extremity or ankle/brachial index of 0.5 or less	60
Claudication on walking between 25 and 100 yards on a level grade at 2 miles per hour, and; trophic changes (thin skin, absence of hair, dystrophic nails) or ankle/brachial index of 0.7 or less	40
Claudication on walking more than 100 yards, and; diminished peripheral pulses or ankle/brachial index of 0.9 or less	20

Note (1): The ankle/brachial index is the ratio of the systolic blood pressure at the

ankle (determined by Doppler study) divided by the simultaneous brachial artery

systolic blood pressure. The normal index is 1.0 or greater.

7444 Autorio a la regia a blitarana.

Note (2): Evaluate residuals of aortic and large arterial bypass surgery or arterial graft as arteriosclerosis obliterans.

Note (3): These evaluations are for involvement of a single extremity. If more than one extremity is affected, evaluate each extremity separately and combine (under § 4.25), using the bilateral factor (§ 4.26), if applicable.

# 7114 Peripheral arterial disease: At least one of the following: ankle/brachial index less than or equal to 0.39; ankle pressure less than 50 mm Hg; toe pressure less than 30 mm Hg; or transcutaneous oxygen tension less than 30 mm Hg

At least one of the following: ankle/brachial index of 0.40-0.53; ankle pressure of 50-65 mm Hg; toe pressure of 30-39 mm Hg; or transcutaneous oxygen tension of 30-39 mm Hg

At least one of the following: ankle/brachial index of 0.54-0.66; ankle

pressure of 66-83 mm Hg; toe pressure of 40-49 mm Hg; or transcutaneous oxygen tension of 40-49 mm Hg
At least one of the following: ankle/brachial index of 0.67-0.79; ankle

100

60

40

At least one of the following: ankle/brachial index of 0.67-0.79; ankle

20
pressure of 84-99 mm Hg; toe pressure of 50-59 mm Hg; or
transcutaneous oxygen tension of 50-59 mm Hg

Note (1): The ankle/brachial index (ABI) is the ratio of the systolic blood pressure at

the ankle divided by the simultaneous brachial artery systolic blood pressure. For the purposes of this diagnostic code, normal ABI will be greater than or equal to 0.80. The ankle pressure (AP) is the systolic blood pressure measured at the ankle. Normal AP is greater than or equal to 100 mm Hg. The toe pressure (TP) is the systolic blood pressure measured at the great toe. Normal TP is greater than or equal to 60 mm Hg. Transcutaneous oxygen tension (TcPO<sub>2</sub>) is measured at the first intercostal space on the foot. Normal is greater than or equal to 60 mm Hg. All measurements must be determined by objective testing.

Note (2): Select the highest impairment value of ABI, AP, TP, or TcPO2 for evaluation.

Note (3): Evaluate residuals of aortic and large arterial bypass surgery or arterial graft as peripheral arterial disease.

Note (4): These evaluations involve a single extremity. If more than one extremity is affected, evaluate each extremity separately and combine (under § 4.25), using the bilateral factor (§ 4.26), if applicable.

7115 Thrombo-angiitis obliterans (Buerger's Disease):	
Ischemic limb pain at rest, and; either deep ischemic ulcers or ankle/brachial index of 0.4 or less	100
Claudication on walking less than 25 yards on a level grade at 2 miles per hour, and; either persistent coldness of the extremity or ankle/brachial index of 0.5 or less	60
Claudication on walking between 25 and 100 yards on a level grade at 2 miles per hour, and; trophic changes (thin skin, absence of hair, dystrophic nails) or ankle/brachial index of 0.7 or less	40
Claudication on walking more than 100 yards, and; diminished peripheral pulses or ankle/brachial index of 0.9 or less  Note (1): The ankle/brachial index is the ratio of the systolic blood pressure at the	20

Note (2): These evaluations are for involvement of a single extremity. If more than one extremity is affected, evaluate each extremity separately and combine (under § 4.25), using the bilateral factor (§ 4.26), if applicable.

ankle (determined by Doppler study) divided by the simultaneous brachial artery

systolic blood pressure. The normal index is 1.0 or greater.

#### 7117 Raynaud's syndrome:

With two or more digital ulcers plus autoamputation of one or more digits	100
and history of characteristic attacks	
With two or more digital ulcers and history of characteristic attacks	60
Characteristic attacks occurring at least daily	40
Characteristic attacks occurring four to six times a week	20
Characteristic attacks occurring one to three times a week	10
Note: For purposes of this section, characteristic attacks consist of sequential co	olor
changes of the digits of one or more extremities lasting minutes to hours, somet	imes
with pain and paresthesias, and precipitated by exposure to cold or by emotiona	ıl
upsets. These evaluations are for the disease as a whole, regardless of the num	ıber
of extremities involved or whether the nose and ears are involved.	

7115 Thrombo-angiitis obliterans (Buerger's Disease):	
Lower extremity: Rate under DC 7114	
Upper extremity:	
Deep ischemic ulcers and necrosis of the fingers with persistent coldness	100
of the extremity, trophic changes with pains in the hand during physical	
activity, and diminished upper extremity pulses	
Persistent coldness of the extremity, trophic changes with pains in the	60
hands during physical activity, and diminished upper extremity pulses	
Trophic changes with numbness and paresthesia at the tips of the fingers,	40
and diminished upper extremity pulses	
Diminished upper extremity pulses	20

Note (1): These evaluations involve a single extremity. If more than one extremity is affected, evaluate each extremity separately and combine (under § 4.25), using the bilateral factor (§ 4.26), if applicable.

Note (2): Trophic changes include, but are not limited to, skin changes (thinning, atrophy, fissuring, ulceration, scarring, absence of hair) as well as nail changes (clubbing, deformities).

## 7117 Raynaud's syndrome (also known as secondary Raynaud's phenomenon or secondary Raynaud's):

100

With two or more digital ulcers plus auto-amputation of one or more digits

and history of characteristic attacks	
With two or more digital ulcers and history of characteristic attacks	60
Characteristic attacks occurring at least daily	40
Characteristic attacks occurring four to six times a week	20
Characteristic attacks occurring one to three times a week	10
Note (1): For purposes of this section, characteristic attacks consist of sequential	
color changes of the digits of one or more extremities lasting minutes to hours,	
sometimes with pain and paresthesias, and precipitated by exposure to cold or by	
emotional upsets. These evaluations are for Raynaud's syndrome as a whole,	
regardless of the number of extremities involved or whether the nose and ears are	
involved.	

Note (2): This section is for evaluating Raynaud's syndrome (secondary Raynaud's phenomenon or secondary Raynaud's). For evaluation of Raynaud's disease (also known as primary Raynaud's), see DC 7124.

#### 7118 Angioneurotic edema:

Attacks without laryngeal involvement lasting one to seven days or longer and occurring more than eight times a year, or; attacks with laryngeal involvement of any duration occurring more than twice a year

Attacks without laryngeal involvement lasting one to seven days and occurring five to eight times a year, or; attacks with laryngeal involvement of any duration occurring once or twice a year

Attacks without laryngeal involvement lasting one to seven days and occurring two to four times a year

7118 No change

#### 7119 Erythromelalgia:

Characteristic attacks that occur more than once a day, last an average of more than two hours each, respond poorly to treatment, and that restrict most routine daily activities

Characteristic attacks that occur more than once a day, last an average of more than two hours each, and respond poorly to treatment, but that do not restrict most routine daily activities

Characteristic attacks that occur daily or more often but that respond to treatment

Characteristic attacks that occur less than daily but at least three times a

Note: For purposes of this section, a characteristic attack of erythromelalgia consists of burning pain in the hands, feet, or both, usually bilateral and symmetrical, with increased skin temperature and redness, occurring at warm ambient temperatures. These evaluations are for the disease as a whole, regardless of the number of extremities involved.

#### 7119 No change

#### 7120 Varicose veins:

week and that respond to treatment

With the following findings attributed to the effects of varicose veins:	100
Massive board-like edema with constant pain at rest	
Persistent edema or subcutaneous induration, stasis pigmentation or	60
eczema, and persistent ulceration	
Persistent edema and stasis pigmentation or eczema, with or without	40
intermittent ulceration	
Persistent edema, incompletely relieved by elevation of extremity, with or	20
without beginning stasis pigmentation or eczema	
Intermittent edema of extremity or aching and fatigue in leg after prolonged	10
standing or walking, with symptoms relieved by elevation of extremity or	
compression hosiery	
Asymptomatic palpable or visible varicose veins	0
	_

#### 7120 Varicose veins:

Evaluate under diagnostic code 7121.

Note: These evaluations are for involvement of a single extremity. If more than one extremity is involved, evaluate each extremity separately and combine (under § 4.25), using the bilateral factor (§ 4.26), if applicable.

7404 Post while hit and drawn of any stick and	
7121 Post-phlebitic syndrome of any etiology:	
With the following findings attributed to venous disease:	
Massive board-like edema with constant pain at rest	100
Persistent edema or subcutaneous induration, stasis pigmentation or eczema, and persistent ulceration	60
Persistent edema and stasis pigmentation or eczema, with or without intermittent ulceration	40
Persistent edema, incompletely relieved by elevation of extremity, with or without beginning stasis pigmentation or eczema	20
Intermittent edema of extremity or aching and fatigue in leg after prolonged standing or walking, with symptoms relieved by elevation of extremity or compression hosiery	10
Asymptomatic palpable or visible varicose veins	0
Note: These evaluations are for involvement of a single extremity. If more than extremity is involved, evaluate each extremity separately and combine (under § using the bilateral factor (§ 4.26), if applicable.	

#### 7121 No change

#### 7122 Cold injury residuals:

With the following in affected parts:

Arthralgia or other pain, numbness, or cold sensitivity plus two or more of the following: tissue loss, nail abnormalities, color changes, locally impaired sensation, hyperhidrosis, X-ray abnormalities (osteoporosis, subarticular punched out lesions, or osteoarthritis)

Arthralgia or other pain, numbness, or cold sensitivity plus tissue loss, nail abnormalities, color changes, locally impaired sensation, hyperhidrosis, or X-ray abnormalities (osteoporosis, subarticular punched out lesions, or osteoarthritis)

Arthralgia or other pain, numbness, or cold sensitivity

#### 7122 Cold injury residuals:

With the following in affected parts:

Arthralgia or other pain, numbness, or cold sensitivity plus two or more of the following: tissue loss, nail abnormalities, color changes, locally impaired sensation, hyperhidrosis, <u>anhydrosis</u>, X-ray abnormalities (osteoporosis, subarticular punched-out lesions, or osteoarthritis), <u>atrophy or fibrosis of the affected musculature</u>, flexion or extension deformity of <u>distal joints</u>, volar fat pad loss in fingers or toes, avascular necrosis of <u>bone</u>, chronic ulceration, carpal or tarsal tunnel syndrome

30

20

10

Arthralgia or other pain, numbness, or cold sensitivity plus one of the following: tissue loss, nail abnormalities, color changes, locally impaired sensation, hyperhidrosis, <u>anhydrosis</u>, X-ray abnormalities (osteoporosis, subarticular punched-out lesions, or osteoarthritis), <u>atrophy or fibrosis of the affected musculature</u>, flexion or extension deformity of distal joints, <u>volar fat pad loss in fingers or toes</u>, <u>avascular necrosis of bone</u>, <u>chronic ulceration</u>, carpal or tarsal tunnel syndrome

Arthralgia or other pain, numbness, or cold sensitivity

November 2021 18

30

20

Note (1): Separately evaluate amputations of fingers or toes, and complications such as squamous cell carcinoma at the site of a cold injury scar or peripheral neuropathy, under other diagnostic codes. Separately evaluate other disabilities that have been diagnosed as the residual effects of cold injury, such as Raynaud's phenomenon, muscle atrophy, etc., unless they are used to support an evaluation under diagnostic code 7122.

Note (2): Evaluate each affected part (e.g., hand, foot, ear, nose) separately and combine the ratings in accordance with §§4.25 and 4.26.

Note (1): Separately evaluate amputations of fingers or toes, and complications such as squamous cell carcinoma at the site of a cold injury scar or peripheral neuropathy, under other diagnostic codes. Separately evaluate other disabilities diagnosed as the residual effects of cold injury, such as Raynaud's syndrome (which is otherwise known as secondary Raynaud's phenomenon), muscle atrophy, etc., unless they are used to support an evaluation under diagnostic code 7122.

Note (2): Evaluate each affected part (e.g., hand, foot, ear, nose) separately and combine the ratings in accordance with §§ 4.25 and 4.26.

#### 7123 Soft tissue sarcoma (of vascular origin)

100

Note: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.

#### 7124 NEW!!

#### 7123 No change

involved.

#### 7124 Raynaud's disease (also known as primary Raynaud's):

Characteristic attacks associated with trophic change(s), such as tight, shiny skin

Characteristic attacks without trophic change(s)

Note (1): For purposes of this section, characteristic attacks consist of intermittent and episodic color changes of the digits of one or more extremities, lasting minutes or longer, with occasional pain and paresthesias, and precipitated by exposure to cold or by emotional upsets. These evaluations are for the disease as a whole, regardless of the number of extremities involved or whether the nose and ears are

10

Note (2): Trophic changes include, but are not limited to, skin changes (thinning, atrophy, fissuring, ulceration, scarring, absence of hair) as well as nail changes (clubbing, deformities).

Note (3): This section is for evaluating Raynaud's disease (primary Raynaud's). For evaluation of Raynaud's syndrome (also known as secondary Raynaud's phenomenon, or secondary Raynaud's), see DC 7117.